Bis (thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 20, Issue 1, 2010, Pages 49-55

  Fodero Tavoletti, Michelle T ^a,b,c   Villemagne, Victor L ^a,c,d   Paterson, Brett M ^a,b   White, Anthony R ^a,c   Li, Qiao Xin ^a,c   Camakaris, James ^a   O'keefe, Graeme ^d   Cappai, Roberto ^a,b,c   Barnham, Kevin J ^a,b,c   Donnelly, Paul S ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; copper homeostasis; copper radiopharmaceuticals; diagnostic imaging; positron emission tomography (PET)

Indexed keywords

BIS(THIOSEMICARBAZONATO) CU 64 COMPLEX; COPPER 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 77954479715     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1359     Document Type: Article

References (37)

1. Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 97, 1700-1725. (Pubitemid 43873662)
2. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
3. Walsh DM, Selkoe DJ (2007) Abeta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
4. Bush AI, Pettingell WH, Multhaup G, Paradis Md, Vonsattel J-P, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994) Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science 265, 1464-1467.
5. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52.
6. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi RE, Bush AI (1998) Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273, 12817-12826.
7. Atwood CS, Huang X, Khatri A, Scarpa RC, Kim Y-S, Moir RD, Tanzi RE, Roher AE, Bush AI (2000) Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol 46, 777-783.
8. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI (2000) Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1-42. J Neurochem 75, 1219-1233.
9. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling K-Q, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI (2004) Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43, 560-568.
10. White AR, Reyes R, Mercer JFB, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R (1999) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842, 439-444.
11. Maynard CJ, Cappai R,Volitakis I, Cherny RA, Masters CL, Li Q-X, Bush AI (2006) Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: Implications for Alzheimer .beta.-amyloid pathology. J Inorg Biochem 100, 952-962.
12. Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, Williamson NA, White AR, Hinds MG, Norton RS, Beyreuther K, Masters CL, Parker MW, Cappai R (2003) Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. J Biol Chem 2778, 17401-17407.
13. Himes RA, Park GY, Siluvai GS, Blackburn NJ, Karlin KD (2008) Structural studies of copper (I) complexes of amyloid-beta peptide fragments: formation of two-coordinate bis(histidine) complexes. Angewandte Chem Int Ed 47, 9084-9087.
14. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
15. Schugar H, Green DE, Bowen ML, Scott LE, Storr T, Bohmerle K, Thomas F, Allen DD, Lockman PR, Merkel M, Thompson KH, Orvig C (2007) Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angewandte Chem Int Ed 46, 1716-1718.
16. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RMD, Evin G, Cherny RA, Hill AF, Barnham KJ, Li Q-X, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281, 17670-17680.
17. Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li Q-X, Masters CL, Barnham KJ, White AR (2008) Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 283, 4568-4577.
18. Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li Q-X, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR, Barnham KJ (2009) Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 106, 381-386.
19. Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6- substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46, 2740-2754.
20. Mathis CA, Lopresti BJ, Klunk WE (2007) Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34, 809-822.
21. Ng S, Villemagne VL, Berlangieri SU, Lee S-T, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC (2007) Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 48, 547-552.
22. Blower PJ, Lewis JS, Zweit J (1996) Copper Radionuclides and Radiopharmaceuticals in Nuclear Medicine. Nucl Med Biol 23, 957.
23. Gingras BA, Suprunchuk T, Bayley CH (1962) The preparation of some thiosemicarbazones and their copper complexes. Can J Chem 40, 1053.
24. Blower PJ, Castle TC, Cowley AR, Dilworth JR, Donnelly PS, Labisbal E, Sowrey FE, Teat SJ, Went MJ (2003) Structural trends in copper(ii) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans, 4416-4425.
25. French FA, Freelander BL (1958) Carcinostatic action of polycarbonyl compounds and their derivatives. IV. Glyoxal bis (thiosemicarbazone) and derivatives. Cancer Res 18, 1290-1300.
26. Beraldo H, Boyd LP,WestDX(1998) Copper(II) and nickel(II) complexes of glyoxaldehyde bis((N3)-substituted thiosemicarbazones). Transition Met Chem 23, 67-71.
27. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan InstituteWorking Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56, 1095-1097.
28. Bonnitcha PD, Vavere AL, Lewis JS, Dilworth JR (2008) In Vitro and In Vivo Evaluation of Bifunctional Bisthiosemicarbazone 64Cu-Complexes for the Positron Emission Tomography Imaging of Hypoxia. J Med Chem 51, 2985-2991.
29. Lewis Jason S, Laforest R, Dehdashti F, Grigsby Perry W, Welch Michael J, Siegel Barry A (2008) An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 49, 1177-1182.
30. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A (1997) Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38, 1155-1160.
31. Dearling JLJ, Lewis JS, McCarthy DW, Welch MJ, Blower PJ (1998) Redox-active metal complexes for imaging hypoxic tisssues: structure-activity relationships in Cu(II) bis(thiosemicarbazone) complexes. J Chem Soc Chem Commun, 2531.
32. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GED (2002) Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 45, 1420.
33. Xiao Z, Donnelly PS, Zimmermann M, Wedd AG (2008) Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. Insights into mechanisms of copper uptake and hypoxia selectivity. Inorg Chem 47, 4338-4347.
34. Dearling JLJ, Lewis JS, Mullen GD, Welch MJ, Blower PJ (2002) Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 7, 249-259.
35. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y,Welch MJ (1999) Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40, 177-183.
36. Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI (2006) Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn2+complexes in Alzheimer's disease. Aging Cell 5, 69-79.
37. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang G-f, Shao L, DeKosky ST, Price JC, Mathis CA (2005) Binding of the positron emission tomography tracer pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25, 10598-10606.